This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Big Pharma Stock Making Gains (and The One Suffering Big Losses)

NEW YORK (TheStreet) -- While the biopharmaceutical industry as a whole has had an impressive year, not every stock in sector was celebrating on Monday. Small-caps Merrimack Pharmaceuticals (MACK - Get Report) and Orexigen Therapeutics (OREX - Get Report) were making moves but in opposite directions.

Orexigen Therapeutics, which specializes in drug treatments for obesity, had plummeted 7% to $6.37 by mid-morning. Earlier in the day, the company announced a proposed offering of $100 million in convertible senior notes due 2020 to institutional investors. Initial buyers will also have a 13-day option to purchase an additional $15 million in notes.

Prior to the announcement, shares had run up 30.1% over the year, short of the 63.4% in gains the iShares NASDAQ Biotechnology Index ETF (IBB)IBB has seen since January.

More typical of the sector in 2013, Merrimack had gained 4% to $4.10, a residual effect of last Tuesday's announcement the company had partnered with global pharmaceutical leader Actavis. The Cambridge, Mass.-based business signed a 10-year partnership agreement with Actavis to develop new treatments using the former's nanoliposomal technology.

Must Read: Why Petrobras (PBR) is Falling Today

Merrimack will receive up to $15.5 million, $2 million of which will be upfront, as part of the agreement. It will also have a "double-digit share of net profits on global sales", according to the company's SEC filing.

The developments signal a welcome turnaround for the company's share prices which had suffered a 48.4% year-to-date loss prior to the announcement. Over the four trading days since, shares have soared 31.2%.

--Written by Keris Alison Lahiff.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MACK $7.08 0.00%
OREX $0.45 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs